Shares of Castle Biosciences Inc. (CSTL), which touched a 52-week low of $9.26 last June, have climbed steadily and now trade around $21. Notably, the stock was once trading over $100 during its heydays in 2021.
This diagnostics company offers tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher Barrett's Esophagus Assay and IDgenetix, a cheek swab test to guide medication management for patients' neuropsychiatric conditions, such as depression and anxiety, are the company's commercially available tests.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com